Promising Developments in Mural Oncology Plc's ARTISTRY-7 Trial Boost Buy Rating
H.C. Wainwright Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $18
HC Wainwright & Co. Reiterates Buy on Mural Oncology, Maintains $18 Price Target
Analysts Offer Insights on NA Companies: Viking Holdings Ltd (VIK) and Mural Oncology Plc (MURA)
Mural Oncology | 10-K: FY2024 Annual Report
Mural Oncology | 8-K: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Mural Oncology Q4 2024 GAAP EPS $(2.01) Misses $(1.96) Estimate
Mural Oncology: Cash, Cash Equivalents, and Marketable Securities Expected to Fund Ops Into 1Q of 2026 >MURA
Express News | Mural Oncology PLC: Cash Runway Extended Into Q1 2026 Through Operational Efficiencies
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Mural Oncology 4Q Loss $34.3M >MURA
Mural Oncology 4Q Loss/Shr $2.01 >MURA
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully
JonesTrading Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $16
Mural Oncology Initiated at Buy by Jones Trading
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Jones Trading Initiates Coverage On Mural Oncology With Buy Rating, Announces Price Target of $16
JonesTrading Initiates Mural Oncology(MURA.US) With Buy Rating, Announces Target Price $16
Optimistic Buy Rating for Mural Oncology Plc Driven by Promising Pipeline Developments and Financial Stability